AI assistant
CALIX, INC — Director's Dealing 2025
Feb 4, 2025
31174_dirs_2025-02-04_deca2d64-1c13-4bd8-9752-00540baf00f0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CALIX, INC ((CALX))
CIK: 0001406666
Period of Report: 2025-01-31
Reporting Person: Collins John Matthew (Chief Commercial Ops Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-01-31 | Stock Option (right to buy) | $34.26 | A | 107775 | Acquired | 2034-02-08 | Common Stock (107775) | Direct |
| 2025-01-31 | Stock Option (right to buy) | $34.26 | A | 68850 | Acquired | 2034-02-08 | Common Stock (68850) | Direct |
| 2025-01-31 | Stock Option (right to buy) | $39.68 | A | 195000 | Acquired | 2035-01-31 | Common Stock (195000) | Direct |
Footnotes
F1: On February 8, 2024, the reporting person was granted a performance-based stock option to purchase 225,000 shares of common stock. On January 31, 2025, the Talent and Compensation Committee (the Committee) of the Board of Directors of Calix, Inc. (Calix) determined that the performance criteria governing 47.9% of the grant had been achieved, resulting in 107,775 shares of common stock remaining subject to the option. The option vests: (i) as to 25% of the shares of common stock subject to the option, on February 8, 2025; and (ii) as to the remaining 75% of the shares of common stock subject to the option, quarterly in equal installments over 36 months from February 8, 2025, subject to continued employment with Calix through the applicable vesting dates.
F2: On February 8, 2024, the reporting person was granted a performance-based option to purchase 75,000 shares of common stock. On January 31, 2025, the Committee determined that the performance criteria governing 91.8% of the grant had been achieved, resulting in 68,850 shares of common stock remaining subject to the option. The option vests: (i) as to 25% of the shares of common stock subject to the option, on February 8, 2025; and (ii) as to the remaining 75% of the shares of common stock subject to the option, quarterly in equal installments over 36 months from February 8, 2025, subject to continued employment with Calix through the applicable vesting dates.
F3: The option vests: (i) as to 25% of the shares of common stock subject to the option, on January 31, 2026; and (ii) as to the remaining 75% of the shares of common stock subject to the option, quarterly in equal installments over 36 months from January 31, 2026, subject to continued employment with Calix through the applicable vesting dates.